1. Home
  2. AKBA vs EQBK Comparison

AKBA vs EQBK Comparison

Compare AKBA & EQBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$1.42

Market Cap

729.1M

Sector

Health Care

ML Signal

HOLD

Logo Equity Bancshares Inc.

EQBK

Equity Bancshares Inc.

HOLD

Current Price

$47.28

Market Cap

870.8M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKBA
EQBK
Founded
2007
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
729.1M
870.8M
IPO Year
2014
2015

Fundamental Metrics

Financial Performance
Metric
AKBA
EQBK
Price
$1.42
$47.28
Analyst Decision
Strong Buy
Hold
Analyst Count
6
5
Target Price
$5.92
$50.50
AVG Volume (30 Days)
3.1M
90.7K
Earning Date
03-12-2026
01-21-2026
Dividend Yield
N/A
1.52%
EPS Growth
N/A
N/A
EPS
N/A
1.23
Revenue
$225,071,000.00
$199,739,000.00
Revenue This Year
$52.41
$76.83
Revenue Next Year
$21.57
$4.61
P/E Ratio
N/A
$38.61
Revenue Growth
32.49
N/A
52 Week Low
$1.30
$34.11
52 Week High
$4.08
$50.07

Technical Indicators

Market Signals
Indicator
AKBA
EQBK
Relative Strength Index (RSI) 46.10 57.82
Support Level $1.35 $46.80
Resistance Level $1.44 $48.25
Average True Range (ATR) 0.08 1.55
MACD 0.01 0.06
Stochastic Oscillator 42.50 54.28

Price Performance

Historical Comparison
AKBA
EQBK

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About EQBK Equity Bancshares Inc.

Equity Bancshares Inc is a bank holding company. It provides a broad range of financial services to businesses and business owners as well as individuals through network of nearly 71 branches located in Arkansas, Kansas, Missouri and Oklahoma. The majority of the Company's revenues come from interest income on financial instruments, including loans, leases, securities and derivatives. The company also earns revenue from Non-interest income which includes Service charges and fees, Debit card income, Investment Referral Income, Trust Income and Insurance Sales Commissions.

Share on Social Networks: